Yamaguchi M, Nakao S, Ueda M, Takamatsu H, Tamaru Y, Shiobara S, Masauji N, Matsue K, Matsuda T
Third Department of Medicine, Kanazawa University School of Medicine, Japan.
Bone Marrow Transplant. 1995 May;15(5):787-9.
Three marrow transplant recipients with hematologic malignancies (two AML, one myelodysplastic syndrome) experienced prolonged pancytopenia after allogeneic BMT following conditioning with non-TBI regimens containing high-dose busulfan and cyclophosphamide (Bu/CY), despite the use of G-CSF. Early recovery of host-derived hematopoiesis ensued. Although neutrophil counts in these patients exceeded 500 x 10(6)/l by day 30 after transplant, these cells were of host origin. This early recovery of host-derived hematopoiesis has been observed rarely among patients conditioned with TBI-based regimens. When patients conditioned with Bu/CY show delayed hematologic recovery, mixed chimerism should be considered even in the presence of normal neutrophil recovery.
三名患有血液系统恶性肿瘤的骨髓移植受者（两名急性髓细胞白血病，一名骨髓增生异常综合征）在接受含大剂量白消安和环磷酰胺（Bu/CY）的非全身照射方案预处理后进行异基因骨髓移植，尽管使用了粒细胞集落刺激因子（G-CSF），仍经历了长时间的全血细胞减少。随后宿主来源的造血功能早期恢复。尽管这些患者在移植后第30天中性粒细胞计数超过500×10⁶/升，但这些细胞来源于宿主。在接受基于全身照射方案预处理的患者中很少观察到这种宿主来源造血功能的早期恢复。当接受Bu/CY预处理的患者出现血液学恢复延迟时，即使中性粒细胞恢复正常，也应考虑混合嵌合体的存在。
